Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529580 | 1.00 | MEN1 (0.43) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL27716771 | 0.84 | MEN1 (0.41) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL1232330 | 0.83 | MEN1 (0.39) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL3872780 | 0.83 | GSK3B (0.39) | GSK3BCYP2A6LOXL2IMPDH2IMPDH1 | |
| SCHEMBL8874836 | 0.82 | CYP2A6 (0.47) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL27590363 | 0.82 | LOXL2 (0.47) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL1232210 | 0.82 | MEN1 (0.47) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL3374034 | 0.79 | GSK3B (0.37) | GSK3BCYP2A6LOXL2IMPDH2IMPDH1 | |
| SCHEMBL14764201 | 0.79 | MEN1 (0.39) | MEN1TTRALBKMT2ACYP19A1 | |
| SCHEMBL14764497 | 0.79 | MEN1 (0.44) | MEN1TTRALBKMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246795-B | Isoxazoline compound containing ether structure at 4-phenyl para-position, preparation method thereof and application thereof as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-115246795-A | Isoxazoline compound with 4-phenyl para-position containing ether structure, preparation thereof and application thereof as insecticide and bactericide | 瑞普（天津）生物药业有限公司 | 2022-10-28 | — | — | CN | claimed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2024-08-27 | — | — | US | disclosed |
| CN-115246795-B | Isoxazoline compound containing ether structure at 4-phenyl para-position, preparation method thereof and application thereof as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| CN-114591351-B | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-1919916-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | Novartis AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007079929-A2 | SUBSTITUTED TRICYCLIC PIPERIDONE DERIVATIVES | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | MEN1 1609/4885TTR 974/4885ALB 1720/4885 |
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | MEN1 1072/4885TTR 3704/4885ALB 2702/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | MEN1 1624/4885TTR 843/4885ALB 1709/4885 |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | MEN1 2050/4885TTR 3886/4885ALB 2595/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | MEN1 4080/4885TTR 1418/4885ALB 3050/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MEN1 1966/4885TTR 3057/4885ALB 4615/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MEN1 1966/4885TTR 3057/4885ALB 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.